APA (7th ed.) Citation

F, S., A, C., M, M., F, B., C, D. P., M, M., . . . P, C. (2025). Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study. British journal of haematology, 206(2), 644. https://doi.org/10.1111/bjh.19961

Chicago Style (17th ed.) Citation

F, Stella, et al. "Brexucabtagene Autoleucel In-vivo Expansion and BTKi Refractoriness Have a Negative Influence on Progression-free Survival in Mantle Cell Lymphoma: Results from CART-SIE Study." British Journal of Haematology 206, no. 2 (2025): 644. https://doi.org/10.1111/bjh.19961.

MLA (9th ed.) Citation

F, Stella, et al. "Brexucabtagene Autoleucel In-vivo Expansion and BTKi Refractoriness Have a Negative Influence on Progression-free Survival in Mantle Cell Lymphoma: Results from CART-SIE Study." British Journal of Haematology, vol. 206, no. 2, 2025, p. 644, https://doi.org/10.1111/bjh.19961.